Results 41 to 50 of about 84,785 (254)
Molecular Oncology, EarlyView.Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute +4 more
wiley +1 more source
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Molecular Oncology, EarlyView.Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni +11 more
wiley +1 more source
Molecular Oncology, EarlyView.Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau +8 more
wiley +1 more source
Molecular Oncology, EarlyView.We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu +10 more
wiley +1 more source
Synergism level of 124 synergistic NP combinations.
, 2012 VSS, SS, S, MS, sS: very strong, strong, normal, moderate, slight synergism, NA: nearly additive, SA, MA: slight, moderate antagonism.
Chun Yan Tan (115766) +5 more
core +1 more source
Molecular Oncology, EarlyView.Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen +14 more
wiley +1 more source
Synergism pattern switch triggered by psychological stress.
, 2013 In the no or low psychological stress environment (i.e. VIP or epinephrine set close to 0 in the simulation), the index was less than 1, which indicated that BADS112A plus LY294002 has synergistic effect in the whole dose region we considered. Whereas as
George Kulik (371780) +5 more
core +1 more source
Pharmacological interactions: Synergism, or not synergism, that is the question
Current Research in Pharmacology and Drug Discovery, 2021 Calzetta, Luigino, Koziol-White, Cynthia
openaire +4 more sources
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
, 2014 (C) Variation of the parameter pair KTA/kbasal_A in Variant M shows that additive synergism can exist in the absence of NB synergism. kbasal_A increases from 0 to 90% as KTA concurrently decreases from 90 to 0%.
John H. Byrne (145197) +3 more
core +1 more source